Hyponatremia is a crucial complication of therapy with thiazide diuretics. This study compares the epidemiological and biochemical profiles and hospital course of patients using hydrochlorothiazide (HCTZ), indapamide (INDA), and chlorthalidone (CTD) admitted with thiazide-associated hyponatremia (TAH). Data were obtained retrospectively from the hospital's digital registries. The epidemiological and biochemical parameters between the HCTZ, INDA, and CTD groups were compared. The correlation between dose and biochemical parameters in each group was performed. The thiazide groups without diuretic co-medication were compared (HCTZ vs. INDA), and the correlation between dose and biochemical parameters in each group was examined. A comparison of the HCTZ (n = 135), INDA (n = 125), and CTD (n = 27) groups identified differences in serum potassium (s-K; p = 0.03). The hyponatremia correction rate was slower in the CTD group at 96 h after admission (p < 0.001). After the exclusion of diuretic co-medication, the HCTZ group (n = 64/135) showed a higher prevalence of ARBs, s-K (both p < 0.001), and a lower median (IQR) equipotent dose (12.5 (o) mg vs. 2.5 (1.2) mg), prevalence of ACE-I (p < 0.001), and eGFR (p = 0.03), when compared to the INDA group (n = 109/125). In conclusion, except for s-K, we observed no significant difference in biochemical and epidemiological profiles between HCTZ, INDA, and CTD. After excluding the influence of other diuretics, we observed higher s-K in the HCTZ group compared to the INDA group, potentially explained by the lower equipotent dose of HCTZ. The CTD group showed a statistically significant trend of slower hyponatremia correction.

Department of Clinical Biochemistry and Pharmacology Tomas Bata Hospital Zlin Zlín Czech Republic

Department of Clinical Pharmacy Tomas Bata Hospital Zlin Zlín Czech Republic

Department of Internal Medicine Tomas Bata Hospital Zlin Zlín Czech Republic

Department of Physics and Materials Engineering Faculty of Technology Tomas Bata University in Zlín Zlín Czech Republic

Faculty of Medicine Masaryk University Brno Brno Czech Republic

Institute of Clinical Biochemistry and Diagnostics Medical Faculty in Hradec Králové Charles University Prague Prague Czech Republic

See more in PubMed

Ernst M. E. and Fravel M. A., “Thiazide and the Thiazide‐Like Diuretics: Review of Hydrochlorothiazide, Chlorthalidone, and Indapamide,” American Journal of Hypertension 35, no. 7 (2022): 573–586. PubMed

DiNicolantonio J. J., Bhutani J., Lavie C. J., and O'Keefe J. H., “Evidence‐Based Diuretics: Focus on Chlorthalidone and Indapamide,” Future Cardiology 11, no. 2 (2015): 203–217. PubMed

McNally R. J., Morselli F., Farukh B., Chowienczyk P. J., and Faconti L., “A Review of the Prescribing Trend of Thiazide‐Type and Thiazide‐Like Diuretics in Hypertension: A UK Perspective,” British Journal of Clinical Pharmacology 85, no. 12 (2019): 2707–2713. PubMed PMC

Liang W., Ma H., Cao L., Yan W., and Yang J., “Comparison of Thiazide‐Like Diuretics Versus Thiazide‐Type Diuretics: A Meta‐Analysis,” Journal of Cellular and Molecular Medicine 21, no. 11 (2017): 2634–2642. PubMed PMC

Olde Engberink R. H. G., Frenkel W. J., van den Bogaard B., Brewster L. M., Vogt L., and van den Born B. J. H., “Effects of Thiazide‐Type and Thiazide‐Like Diuretics on Cardiovascular Events and Mortality,” Hypertension 65, no. 5 (2015): 1033–1040. PubMed

Ishani A., Cushman W. C., Leatherman S. M., et al., “Chlorthalidone vs. Hydrochlorothiazide for Hypertension–Cardiovascular Events,” New England Journal of Medicine 387, no. 26 (2022): 2401–2410. PubMed

Hripcsak G., Suchard M. A., Shea S., et al., “Comparison of Cardiovascular and Safety Outcomes of Chlorthalidone vs Hydrochlorothiazide to Treat Hypertension,” JAMA Internal Medicine 180, no. 4 (2020): 542–551. PubMed PMC

Edwards C., Hundemer G. L., Petrcich W., et al., “Comparison of Clinical Outcomes and Safety Associated With Chlorthalidone vs Hydrochlorothiazide in Older Adults with Varying Levels of Kidney Function,” JAMA Network Open 4, no. 9 (2021): e2123365. PubMed PMC

Mancia G., Kreutz R., Brunström M., et al., “2023 ESH Guidelines for the Management of Arterial Hypertension The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension: Endorsed by the International Society of Hypertension (ISH) and the European Renal Association (ERA),” Journal of Hypertension 41 (2023): 1874. PubMed

Laboratories S.. “Summary of Product Characteristics: Indapamide,” 2023. [cited 2025‐02‐18], https://www.sukl.cz.

Andersson N. W., Wohlfahrt J., Feenstra B., Hviid A., Melbye M., and Lund M., “Cumulative Incidence of Thiazide‐Induced Hyponatremia,” Annals of Internal Medicine 177 (2024): 1–11. PubMed

Mannheimer B., Bergh C. F., Falhammar H., Calissendorff J., Skov J., and Lindh J. D., “Association Between Newly Initiated Thiazide Diuretics and Hospitalization due to Hyponatremia,” European Journal of Clinical Pharmacology 77, no. 7 (2021): 1049–1055. PubMed PMC

Braun M. M., Barstow C. H., and Pyzocha N. J., “Diagnosis and Management of Sodium Disorders: Hyponatremia and Hypernatremia,” American Family Physician 91 (2015): 299–307. PubMed

Adrogué H. J. and Madias N. E., “Hyponatremia,” New England Journal of Medicine 342 (2000): 1581–1589. PubMed

Rustad P., Felding P., Franzson L., et al., “The Nordic Reference Interval Project 2000: Recommended Reference Intervals for 25 Common Biochemical Properties,” Scandinavian Journal of Clinical and Laboratory Investigation 64 (2004): 271–284. PubMed

Seay N. W., Lehrich R. W., and Greenberg A., “Diagnosis and Management of Disorders of Body Tonicity—Hyponatremia and Hypernatremia: Core Curriculum 2020,” American Journal of Kidney Diseases 75 (2020): 272–286. PubMed

Filippone E. J., Ruzieh M., and Foy A., “Thiazide‐Associated Hyponatremia: Clinical Manifestations and Pathophysiology,” American Journal of Kidney Diseases 75, no. 2 (2020): 256–264. PubMed

Burst V., Grundmann F., Kubacki T., et al., “Thiazide‐Associated Hyponatremia, Report of the Hyponatremia Registry: An Observational Multicenter International Study,” American Journal of Nephrology 45, no. 5 (2017): 420–430. PubMed PMC

Friedman E., Shadel M., Halkin H., and Farfel Z., “Thiazide‐Induced Hyponatremia. Reproducibility by Single Dose Rechallenge and an Analysis of Pathogenesis,” Annals of Internal Medicine 110, no. 1 (1989): 24–30. PubMed

Dhalla I. A., Gomes T., Yao Z., et al., “Chlorthalidone versus Hydrochlorothiazide for the Treatment of Hypertension in Older Adults,” Annals of Internal Medicine 158, no. 6 (2013): 447–455. PubMed

van B. J. C., SM S., Rodenburg E. M., et al., “Risk of Hyponatremia With Diuretics: Chlorthalidone Versus Hydrochlorothiazide,” American Journal of Medicine 127, no. 8 (2014): 763–771. PubMed

Roush G. C., Ernst M. E., Kostis J. B., Tandon S., and Sica D. A., “Head‐to‐Head Comparisons of Hydrochlorothiazide With Indapamide and Chlorthalidone,” Hypertension 65, no. 5 (2015): 1041–1046. PubMed

Ravioli S., Bahmad S., Funk G. C., Schwarz C., Exadaktylos A., and Lindner G., “Risk of Electrolyte Disorders, Syncope, and Falls in Patients Taking Thiazide Diuretics: Results of a Cross‐Sectional Study,” American Journal of Medicine 134, no. 9 (2021): 1148–1154. PubMed

Huang C. C., Chung C. M., Hung S. I., et al., “Clinical and Genetic Factors Associated With Thiazide‐Induced Hyponatremia,” Medicine 94, no. 34 (2015): e1422. PubMed PMC

Ware J. S., Wain L. V., Channavajjhala S. K., et al., “Phenotypic and Pharmacogenetic Evaluation of Patients With Thiazide‐Induced Hyponatremia,” Journal of Clinical Investigation 127, no. 9 (2017): 3367–3374. PubMed PMC

Klhůfek J. and Šálek T., “Thiazide‐Associated Hyponatremia in Internal Medicine Patients: Analysis of Epidemiological and Biochemical Profiles,” Postgraduate Medicine 134, no. 5 (2022): 487–493. PubMed

Klhůfek J. and Vodička M., “Furosemide‐Associated Hyponatremia in Internal Medicine Patients: Analysis of Epidemiological and Biochemical Profiles,” European Journal of Internal Medicine 114 (2023): 138–140. PubMed

Choy K. W., Wijeratne N., Lu Z. X., and Doery J. C., “Harmonisation of Osmolal Gap – Can We Use a Common Formula?” Clinical Biochemist Reviews 37 (2016): 113–119. PubMed PMC

Liamis G., Filippatos T. D., and Elisaf M. S., “Thiazide–Associated Hyponatremia in the Elderly: What the Clinician Needs to Know,” Journal of Geriatric Cardiology 13, no. 2 (2016): 175–182. PubMed PMC

Nadal J., Channavajjhala S. K., Jia W., Clayton J., Hall I. P., and Glover M., “Clinical and Molecular Features of Thiazide‐Induced Hyponatremia,” Current Hypertension Reports 20, no. 4 (2018): 31. PubMed PMC

Mannheimer B., Falhammar H., Calissendorff J., Lindh J. D., and Skov J., “Non‐Thiazide Diuretics and Hospitalization due to Hyponatraemia: A Population‐Based Case‐Control Study,” Clinical Endocrinology 95, no. 3 (2021): 520–526. PubMed

Ueda Y., Ookawara S., Ito K., et al., “Changes in Urinary Potassium Excretion in Patients With Chronic Kidney Disease,” Kidney Research and Clinical Practice 35, no. 2 (2016): 78–83. PubMed PMC

Zillich A. J., Garg J., Basu S., Bakris G. L., and Carter B. L., “Thiazide Diuretics, Potassium, and the Development of Diabetes,” Hypertension 48 (2006): 219–224. PubMed